Fact-checked by Grok 2 weeks ago

Boris Jordan

Boris Jordan (born June 2, 1966) is an American businessman of Russian émigré descent who co-founded Renaissance Capital Group, Russia's first private international investment bank, and serves as Executive Chairman of Curaleaf Holdings, Inc., the largest cannabis company by market share in the United States. Born in to parents who emigrated from the , Jordan graduated from before entering finance, initially working at and later co-heading the Moscow office of during Russia's post-Soviet in the early . In 1995, he established with partners, facilitating equity offerings and advisory services that helped privatize state assets and attract foreign investment into emerging Russian markets, amassing personal wealth estimated in the billions. Transitioning from Russia amid political turbulence, Jordan founded the Sputnik Group (later SPK Group) for private equity and advisory work, retaining stakes in entities like Renaissance Insurance while pivoting to the U.S. cannabis sector, where he orchestrated 's growth through acquisitions and public listing, positioning it as a vertically integrated operator across multiple states. His career has drawn over ties to entities, including funding from sanctioned individuals for cannabis ventures, prompting regulatory investigations into disclosures and product compliance at , though Jordan maintains these connections predate geopolitical conflicts and do not imply control by foreign interests.

Early Life and Background

Family Origins and Upbringing

Boris Jordan was born in 1966 in , to émigré parents whose families had fled the Bolshevik Revolution. His father, Aleksey Borisovich Jordan, a graduate of a who had lived in as part of the community, and his mother, Maria Alexandrovna Jordan (née Shishkova), who studied at , maintained strong ties to their heritage despite settling in the United States. Jordan's grandfathers, both participants in anti-Bolshevik forces during the , exemplified the displaced that shaped the family's worldview. Raised on in a household steeped in , Jordan spoke the fluently at home and attended supplementary schooling alongside his . This environment, part of a broader Sea Cliff community of White exiles, exposed him to vivid family narratives of pre-revolutionary opulence, Soviet exile, and survival in emigration, sparking an enduring curiosity about . Such stories, passed down from immigrant forebears, highlighted themes of resilience amid upheaval, fostering in Jordan a foundational appreciation for and adaptability. The ethos of his upbringing—marked by entrepreneurial ingenuity to rebuild lives in a new land—instilled practical values that contrasted with broader American suburban norms, priming his later pursuits in volatile markets. Jordan has described this dual identity, educated "at home as a " within the U.S., as cultivating a unique perspective on opportunity amid historical rupture.

Education and Early Influences

Boris Jordan received a from New York University's Washington Square College in 1988, majoring in U.S.-Russian studies with an emphasis on economic relations between the two nations. This curriculum provided foundational knowledge in cross-cultural economic dynamics, including the mechanics of transitioning from command economies to market systems, alongside practical language training in to facilitate engagement with Soviet-era reforms. Born in 1966 in Sea Cliff, New York, to parents of Russian émigré descent, Jordan grew up immersed in family narratives of pre-revolutionary Russia and the disruptions of Soviet rule, which sparked his early fascination with the region's historical and economic upheavals. Complementing his formal American education, he attended supplemental Saturday classes in Russian language, literature, and history, cultivating bilingual proficiency and a nuanced perspective on the inefficiencies of centralized planning versus decentralized market incentives. These influences oriented his intellectual development toward pragmatic analyses of institutional failures in state-controlled systems, equipping him with the analytical framework for evaluating opportunities in post-communist liberalization without reliance on ideological abstractions. Jordan's academic preparation intersected with nascent professional experience immediately after graduation, as he entered U.S. at Kidder, Peabody & Co. in 1987—prior to completing his degree—focusing initially on debt instruments that honed quantitative skills transferable to volatile transitional economies. This early immersion built rigorous capabilities, grounded in empirical assessment of risk and capital flows, which later proved instrumental in navigating culturally distinct business environments.

Entry into Finance and Russian Markets

Initial Roles in Investment Banking

Following his graduation from New York University with a degree in Russian-American economic relations, Boris Jordan entered investment banking in the United States during the late 1980s, joining (CSFB) amid growing interest in post-communist opportunities. By 1992, at age 26, he relocated to to co-head CSFB's Eastern European and Russian operations, serving as managing director of the firm's nascent office. This opportunistic shift aligned with the Soviet Union's dissolution in December 1991, enabling Jordan to navigate the ensuing economic chaos through advisory roles on and the distribution of privatization vouchers to Russian citizens. In , Jordan's team at CSFB focused on bridging Western capital with Russia's privatizing state assets, facilitating early equity transactions in a devoid of established . Over three years, from 1992 to 1995, he contributed to building Russia's equity from rudimentary trading floors to initial international standards, emphasizing private incentives to supplant inefficient state controls amid and institutional voids. This period highlighted the causal advantages of entrepreneurial agility in transitional economies, where rapid outperformed protracted government oversight, as evidenced by CSFB's success in channeling foreign into voucher auctions despite pervasive risks.

Contributions to Russian Privatization and Capital Markets

In 1992, Boris Jordan, then a young banker at (CSFB), relocated to and contributed to Russia's nascent capital markets by supporting the government's efforts, including work with the State Committee on Property (GKI), the agency overseeing asset transfers from state to private hands. His team facilitated the aggregation and trading of privatization vouchers—certificates distributed to over 140 million Russians in 1992 to enable broad-based participation in owning former state enterprises—by convincing foreign investors to purchase approximately $400 million worth, injecting liquidity and establishing early trading mechanisms that evolved into formalized exchanges. This process helped launch the Stock Exchange's precursors, such as over-the-counter voucher markets, which by 1994 handled millions of trades and democratized access to equity ownership for small holders before consolidation by larger players. Jordan's advocacy emphasized transparent pricing and rule-based transactions to counter bureaucratic resistance and insider manipulations, aligning with the voucher system's intent to rapidly disperse ownership and foster market discipline over central planning. Through CSFB, he executed deals acquiring stakes in privatized firms like Sidanko oil and VimpelCom telecom, representing over 10% of the program's total buying power by mid-1994, which accelerated and introduced Western standards for disclosure and valuation. These efforts laid groundwork for Russia's markets, where trading volume grew from negligible levels in 1992 to billions of dollars by the late , enabling wealth generation amid the shift from Soviet-era stagnation—where real GDP per capita hovered around $6,000 with minimal private investment—to post-privatization recovery phases, including average annual growth exceeding 7% from 1999 to 2008 following initial disruptions. Critics, often from academic and media outlets predisposed against rapid , have portrayed as enabling oligarchic capture, yet empirical outcomes refute blanket exploitation narratives: over 70% of large enterprises were privatized by 1996, correlating with a tripling of GDP share from 45% in 1990 to near 70% by 2000, and lifting millions from through emerging and entrepreneurial incentives absent under communism's zero-growth traps. Jordan's role, as a facilitator rather than direct state asset bidder, prioritized market infrastructure—such as standardized exchanges—that mitigated some risks by broadening participation, evidenced by foreign capital inflows exceeding $1 billion in early deals and the survival of privatized firms outperforming state-held ones in productivity metrics post-reform. This infrastructure endured, underpinning Russia's integration into global finance despite subsequent political interventions.

Key Business Ventures in Russia

Renaissance Capital and Financial Innovation

Boris Jordan co-founded Renaissance Capital in 1995, shortly after departing Credit Suisse First Boston, establishing it as Russia's inaugural international investment bank dedicated to emerging markets. The firm initially focused on advisory services, equity research, and capital raising amid the chaotic post-Soviet economic transition, introducing professional standards to a market previously dominated by opaque barter and insider deals. By prioritizing merit-based transactions and institutional frameworks over political connections, Renaissance exemplified a model of financial innovation grounded in market performance rather than state patronage, enabling Jordan to amass wealth through advisory and performance-based fees. Under Jordan's leadership as CEO from 1995 to 1999, pioneered initial public offerings (IPOs) and equity research in , underwriting a significant share of early privatizations and corporate financings that facilitated the shift from state-owned enterprises to private capital markets. The firm handled deals totaling billions in value, including advisory for high-profile equity placements that attracted foreign investment and promoted long-term over short-term speculation. This approach contrasted with prevalent narratives, as evidenced by Renaissance's reliance on expatriate expertise from firms like CSFB to build analytical capabilities, fostering transparency in a sector prone to . The , triggered by ruble devaluation and debt default, severely tested , leading to liquidity strains and amid widespread market contraction. Despite these setbacks, the firm demonstrated resilience by adapting operations, retaining key talent, and repositioning for recovery, which underscored the viability of professional in volatile environments over failure-prone oligarchic models. Jordan's exit in 1999 allowed to evolve into a broader emerging markets player, but its foundational innovations under his tenure laid empirical groundwork for sustainable financial intermediation in .

Pharmstandard and Pharmaceutical Expansion

Pharmstandard emerged as Russia's preeminent pharmaceutical manufacturer in the , scaling production of generics and proprietary drugs to over 400 items, including treatments for and , thereby diminishing reliance on imports that previously dominated 80% of the . The company's growth was propelled by strategic acquisitions and R&D commitments, achieving consolidated manufacturing capacity exceeding 1.7 billion packs annually and 700,000 liters of active substances, positioning it as the sector leader by sales volume. Key milestones included its 2007 , priced at US$58.20 per share and US$14.55 per global , which facilitated expansion amid evolving regulations aimed at localizing production. Listing on the (following earlier RTS preparations) enabled capital raises for facility upgrades and export initiatives, with generics comprising 85% of sales by volume in a market projected to double to $20 billion by 2025 through biosimilars and innovation. incentives, contrasting state-run inefficiencies, drove verifiable output surges, as firms like Pharmstandard addressed supply gaps via affordable local alternatives. Challenges persisted, including patent disputes common in Russia's judicial system, where generic challengers exploited interpretive ambiguities to accelerate market entry, and quality control hurdles resolved through regulatory reforms and facility modernizations. These dynamics underscored causal realism in the sector: market-driven outpaced bureaucratic alternatives, fostering self-sufficiency despite ongoing litigation risks, with exports bolstering against import dependencies.

Shift to Global and U.S.-Focused Enterprises

Founding and Leadership of Curaleaf

Boris Jordan served as the founding investor in Holdings, Inc., originally incorporated as Palliatech in 2014 to capitalize on Florida's emerging market following Amendment 2's approval in 2016, which legalized non-smokable medical marijuana. Under Jordan's strategic direction, the company rebranded to in 2018 and expanded into a vertically integrated multi-state operator, controlling cultivation, processing, manufacturing, and retail dispensaries to optimize efficiency and product quality in states with legalized programs. This model aligned with Jordan's view of markets as consensual, adult-oriented exchanges unburdened by federal prohibition, enabling rapid scaling amid state-level that empirical data shows reduces black-market and generates verifiable tax revenues exceeding prohibition-era enforcement costs. Jordan assumed the role of executive chairman in 2015 upon acquiring majority control, guiding key mergers to build Curaleaf's footprint across 23 U.S. states by 2020. Notable acquisitions included Grassroots Cannabis in July 2020 for approximately $700 million, which added cultivation and dispensary assets in , , and other markets, positioning Curaleaf as the world's largest company by pro forma revenue at the time; and Select in February 2020, enhancing branded product lines like vape cartridges and edibles. These moves emphasized operational synergies, with yielding gross margins above industry averages through proprietary extraction technologies and patient-focused distribution, expanding access to over 1.5 million registered medical patients and recreational consumers in eligible states. Under Jordan's leadership, achieved annual exceeding $1 billion by fiscal year 2021, reaching $1.34 billion in 2023 through consistent year-over-year growth driven by market share gains in high-volume states like and . Efficiency metrics, such as reduced cost per unit cultivated via large-scale greenhouses, mitigated overexpansion risks inherent in fragmented state regulations, though industry-wide price compression from oversupply tested margins in 2023-2024. Jordan's approach prioritized data-backed advocacy, citing longitudinal studies showing negligible public health detriments from regulated adult use compared to , to counter persistent federal barriers that distort capital allocation. In August 2024, he transitioned to CEO alongside his chairmanship, focusing on profitability amid maturing U.S. markets.

International Growth and Strategic Acquisitions

Under Boris Jordan's leadership as executive chairman, expanded its international footprint in through targeted acquisitions and ownership consolidations, capitalizing on regulatory reforms in markets. In February 2024, International acquired Can4Med, a distributor, to bolster its presence in Poland's . Earlier partnerships included a majority stake in Germany's Four 20 Pharma via a €20 million deal, enhancing capabilities in the country's legalized medical framework. By early 2025, entered the through a supply agreement with Astrasana Pharma, further diversifying operations amid 's fragmented but growing addressable market, estimated at $246 billion in 2024 with and the as primary drivers. A pivotal consolidation occurred in July 2025, when bought out the remaining equity stake held by a strategic in International Holdings Limited, regaining 100% ownership effective July 2. This transaction, valued through share issuance rather than cash, streamlined governance and enabled unified decision-making across European subsidiaries, as stated by Jordan: "This consolidation of ownership of International positions us to accelerate our growth strategy in ." Such moves addressed prior joint-venture complexities while retaining the investor's confidence via Holdings shares. In the U.S., complemented international efforts with domestic stabilization strategies amid a patchwork of state regulations, operating across 23 states with 151 dispensaries as of mid-2025. Second-quarter 2025 revenue totaled $315 million, a 1.5% sequential increase from , driven partly by international contributions of $41 million—reflecting 74% year-over-year growth in international sales. Adjusted gross margins reached 49%, outperforming some multi-state operator peers amid pricing pressures, though varies by state due to inconsistent taxation and licensing—e.g., Curaleaf's broad footprint yields advantages over narrower competitors like Trulieve, but exposes it to localized enforcement risks. Prospects hinge on rescheduling potential, which could ease banking and interstate barriers, contrasting Europe's more uniform medical pathways but offset by U.S. state-level ; Curaleaf's international segment generated positive with 50% margins in Q1 2025, underscoring adaptive resilience despite broader sector debt concerns.

Controversies and Public Scrutiny

Allegations of Russian Oligarch Ties

In 2022, following Russia's invasion of Ukraine, media reports highlighted historical financial ties between Boris Jordan, executive chairman of Curaleaf Holdings, and sanctioned Russian oligarch Roman Abramovich, primarily through pre-2019 investments in Curaleaf's predecessor entities. Leaked documents reviewed by investigative outlets revealed that Abramovich, via offshore vehicles like Cetus International, provided over $400 million in funding and loans to Jordan personally, Curaleaf's early incarnation Palliatech, and major shareholder Andrey Blokh between 2016 and 2018, including $130 million in direct investments and $194 million in loans to U.S. cannabis firms. These transactions occurred prior to Abramovich's designation on international sanctions lists in March 2022, and were routed through British Virgin Islands entities to support early-stage cannabis expansion, according to the records. Jordan's prior role at , co-founded in 1995 with connections to oligarchs such as , has fueled speculation of broader Russian influence, though no direct evidence links these 1990s privatization-era dealings to operations. Reports in outlets like and Vice questioned 's "Russian roots" due to Jordan's two decades in and Abramovich's funding, prompting regulatory inquiries in states like and over disclosure adequacy and potential sanctions risks. However, Jordan has consistently denied any ongoing Russian control or influence, stating in December 2022 that Abramovich is not a current shareholder to his knowledge and that the financing supported U.S.-focused growth without strings attached. Curaleaf's public SEC filings as a Nasdaq-listed (CURLF) confirm U.S. institutional investors hold majority ownership, with no disclosed Russian entities exerting control post-2019, countering narratives of foreign dominance amplified by post-invasion scrutiny. No verifiable evidence has emerged of Abramovich or other oligarchs swaying Curaleaf policy, board decisions, or U.S. regulatory interactions, with allegations largely resting on historical capital flows rather than causal influence. State-level probes, such as those by the Massachusetts Cannabis Control Commission in early , focused on reporting transparency but yielded no findings of sanctions violations or undue foreign sway.

Sanctions Risks and Business Responses

In February 2022, following Russia's invasion of Ukraine, social media speculation emerged suggesting that Curaleaf Holdings Inc., where Boris Jordan serves as Executive Chairman, could face U.S. sanctions due to Jordan's and co-founder Andrey Blokh's historical business ties in Russia, including Jordan's past leadership at Renaissance Capital. Curaleaf issued a statement on February 25, 2022, asserting that as a U.S.-domiciled company with American citizen executives, it was not subject to U.S. economic sanctions targeting Russia, and emphasized that Jordan and Blokh held no current operational roles or assets in Russian entities subject to restrictions. Jordan himself described the concerns as primarily a public relations issue stemming from his Russian business heritage rather than any substantive legal risk, noting in a March 2022 interview that Western sanctions would not directly impact U.S. citizens like himself and Blokh. No U.S. or EU sanctions were imposed on , , or its key personnel, allowing the company to maintain uninterrupted operations in the United States and without asset freezes or mandates tied to exposure. Subsequent regulatory in 2023 focused on undisclosed loans from entities linked to sanctioned billionaire , provided through his firm to and Blokh during 's early funding stages (pre-2018 restructuring), prompting investigations by bodies such as the Massachusetts Cannabis Control Commission into disclosure compliance. acknowledged the historical financing as typical for a nascent venture but confirmed repayment and no ongoing ties, with probes resolving without penalties or operational disruptions by 2024. Sanctions frameworks have proven causally limited in targeting private Western-based actors with attenuated past connections, as opposed to state-aligned oligarchs or entities, evidenced by Curaleaf's sustained compliance with U.S. Treasury guidelines and absence of enforcement actions despite heightened post-2022 reviews. The company's stock experienced volatility amid broader sector pressures and initial sanction rumors in early 2022 but stabilized without sanction-induced collapses, reflecting the inefficacy of broad punitive measures against non-proximate private holdings.

Personal Life and Legacy

Family and Residences

Boris Jordan is married to Elizabeth Jordan, who serves as CEO of Elizabeth Jordan Photography. He has five children. Jordan has maintained a private family life, with limited public details on his children's activities beyond their independent pursuits and no reported personal scandals involving them. During his extensive business tenure in Russia from the early 1990s through much of the 2000s, Jordan resided primarily in . Upon shifting focus to U.S.-based ventures, his residences centered in , listed as his primary location. He acquired an oceanfront penthouse in Miami Beach in 2015 for approximately $20 million, later selling it in 2018 for $26 million.

Philanthropic Efforts and Public Persona

Jordan and his wife Elizabeth, both alumni, established the Jordan Center for the Advanced Study of at NYU in 2011 through a substantial family donation, promoting scholarly research on history, to bridge Russian-American intellectual ties. The family further contributed major underwriting to the New York Public Library's 2003 exhibition "Russia Engages the World," which highlighted centuries of artistic and diplomatic interactions with global cultures, including artifacts from émigré communities. These targeted gifts reflect a focus on heritage preservation rather than broad-scale charitable foundations, with no public records of multimillion-dollar endowments to general welfare causes. At , under Jordan's executive oversight since 2014, the company has prioritized patient support, including wholesale supply to European markets like and for therapeutic use, and initiatives emphasizing regulatory accountability to protect patient access. In 2025, partnered with The Baldwin Fund for a nationwide research fundraiser, enabling customer donations via round-ups at dispensaries to fund clinical advancements, aligning corporate operations with without diverting core profits to unrelated philanthropy. Jordan presents himself publicly as a advocate, frequently critiquing state-level barriers to markets in appearances, such as a May 2025 statement denouncing regulators under Governor as "un-American" for impeding medical sales he pioneered there. In a January 2025 interview, he highlighted hemp-derived products as a pathway to federal reform under the incoming administration, positioning Curaleaf's growth—from a 2013 seed investment to a multibillion-dollar entity—as evidence of market innovation over bureaucratic dependency. This self-narrative counters scrutiny of his business history by emphasizing U.S.-born entrepreneurialism and post-Soviet experience as drivers of value creation, with estimating his at $1.2 billion tied to equity as of 2024.

References

  1. [1]
    Boris Jordan - Forbes
    ... Boris Jordan on the 2022 Billionaires. ... Jordan still has a stake in Renaissance Insurance, a leading insurer in Russia.
  2. [2]
    Jordan Boris Alekseyevich - rutelegraf.com
    Biography: Boris Jordan was born on June 2, 1966 in New York (USA) in a family of Russian immigrants. His grandfather was the minister of education in the ...
  3. [3]
    Boris Jordan - Cannabis Europa
    Boris Jordan is an American businessman and the co-founder of Renaissance Capital Group, an international investment and advisory firm and SPK Group.
  4. [4]
    Boris Jordan: Positions, Relations and Network - MarketScreener
    Boris Jordan was co-founder and CEO of Renaissance Capital Group, Russia's first international investment bank. From 1992 to 1995, Boris Jordan co-headed the ...
  5. [5]
    How Russia Prepared Renaissance Capital Co-Founder Boris ...
    and how his experience in wide-open 1990s ...
  6. [6]
    [PDF] CURALEAF HOLDINGS, INC. - Odyssey Trust Company
    May 6, 2024 · Mr. Jordan is an American businessman, co-founder of Renaissance Capital Group and The Sputnik Group (now known as SPK Group), two ...
  7. [7]
    What do we really know about the Russian roots of ... - The Guardian
    Jul 19, 2022 · Curaleaf could be worth $75bn by 2030. But its US-born chair, Boris Jordan, faces questions over his two decades in Russia.Missing: achievements | Show results with:achievements
  8. [8]
    Curaleaf Controversies - Project CBD
    Feb 6, 2023 · Russian oligarch money, product safety violations, and unfair labor practices at a giant, scandal-ridden cannabis company.Missing: achievements | Show results with:achievements
  9. [9]
    No, The World's Biggest Cannabis Company Is Not Russian-Owned
    Mar 4, 2022 · Despite being American, billionare Curaleaf founder Boris Jordan says his cannabis company is being unfairly targeted because of his Russian ...Missing: achievements | Show results with:achievements
  10. [10]
    Boris Jordan Net Worth, Biography, Age, Spouse, Children & More
    Boris Jordan co-founded Renaissance Capital investment group with Stephen Jennings. November 1998 - February 1999. Boris Jordan was recommended by Vladimir ...
  11. [11]
    To Russia, With Capital - The Washington Post
    May 13, 2001 · Jordan grew up in an immigrant home, speaking Russian with his parents and attending Russian school on the side. Both grandfathers fought with ...Missing: upbringing | Show results with:upbringing
  12. [12]
    American Media Mogul Makes News in Moscow - The New York Times
    Jul 22, 2001 · ... Boris Jordan started running the place. ... He grew up in Sea Cliff, L.I., in a community of displaced White Russian aristocrats and attended ...
  13. [13]
    An American In Moscow - The New York Times
    Sep 20, 1995 · Growing up on Long Island, the grandson of Russian immigrants, Boris Jordan was fascinated by his family's native land and dreamed of returning ...
  14. [14]
    The White Russians from Long Island - Euromoney
    Aug 1, 1996 · The younger generation of Russian Americans are following in the footsteps of Boris Jordan, who arrived in Moscow when he was 25. Whenever Boris ...Missing: immigrant | Show results with:immigrant
  15. [15]
    Commanding Heights : Boris Jordan | on PBS
    An American of Russian ancestry, Boris Jordan was a key figure in Russia's economic transition to capitalism in the early '90s, assisting in the launch of the ...
  16. [16]
    Boris Jordan: The Man Who Made Moscow's Market - Bloomberg.com
    May 21, 1995 · As a New York University undergraduate in the 1980s, he majored in U.S.-Russian studies. Right after college, he joined Kidder, Peabody & Co.
  17. [17]
    Cannabis King: Boris Jordan, Chairman Of Curaleaf, Becomes The ...
    Sep 10, 2019 · After graduating from New York University, where he sits on the school's board of trustees, he got his start in 1987 at the now-defunct ...
  18. [18]
    Ex-Banker Builds Billion-Dollar Fortune as Legal Pot Sweeps U.S.
    Jul 17, 2019 · Boris Jordan's 31% Curaleaf stake worth more than $1 billion; NYU graduate is capitalizing on spreading legalization of weed.
  19. [19]
    Commanding Heights : Boris Jordan | on PBS
    An American of Russian ancestry, Boris Jordan was a key figure in Russia's economic transition to capitalism in the early '90s, assisting in the launch of the ...
  20. [20]
    https://www.barrons.com/articles/curaleaf-is-an-american-marijuana-company-with-russian-roots-1542798001
  21. [21]
    Insecurities | Zero Sum: The Arc of International Business in Russia
    Aug 21, 2025 · In a lengthy interview with the PBS programme Commanding Heights, then CSFB Russia head Boris Jordan ... Investment Banking,” Bloomberg, 11 Mar.
  22. [22]
    Table: Boris Jordan: The Buying and Selling of Russia - Bloomberg
    Apr 29, 2001 · 1992. The 26-year-old Jordan lands a job in Moscow with Credit Suisse First Boston. Two years later, he persuades foreign investors to buy ...
  23. [23]
    [PDF] Privatization and Piratization in Post-Communist Russia
    Boris Jordan, a man of Russian parentage who grew up on Long Island and worked for Credit Suisse First Boston, went to Russia and managed to buy between 7.5 mil ...
  24. [24]
    Boris Jordan | Prohibition Partners LIVE
    Jordan was considered a key player in the development of the Russian stock market and was a leader in the privatization of Russian state assets. Mr. Jordan ...
  25. [25]
    How RenCap reflects Russia's rollercoaster - Euromoney
    Into that world stepped a group of young financial mavericks. Boris Jordan, a financial innovator and driving force in RenCap's early years, now sits on ...
  26. [26]
    The All-Russia Research Team | Institutional Investor
    The founders of Renaissance, led by Boris Jordan, came from CSFB's Moscow office. ... "This will be the biggest indexation event in emerging-markets history," ...
  27. [27]
    https://www.wsj.com/articles/SB1037739832794442628
  28. [28]
    Boris Alexis Jordan - CURA.CA | Curaleaf Holdings Inc.
    Here's Why the Stocks Aren't. Barron's. 08/08/24; MarketWatch.com. Curaleaf founder Boris Jordan to take over as CEO of largest U.S. cannabis company.<|control11|><|separator|>
  29. [29]
    Pharmstandard - Wikipedia
    ^ "BRIEF-Pharmstandard shares to be delisted as of March 24 - Moscow Exchange". Reuters. 17 February 2017. Retrieved 23 April 2017. ^ "Об исключении ценных ...
  30. [30]
    Production - the official website Pharmstandard
    Consolidated manufacturing capacity of the Company. Over 1.7 bln. packs of pharmaceutical products; Over 700 thousand litres of substances.
  31. [31]
    JSC PHARMSTANDARD ANNOUNCES PRICING OF THE ...
    JSC PHARMSTANDARD ANNOUNCES PRICING OF THE OFFERING AT US$58.20 PER SHARE AND US$14.55 PER GDR. 04.05.2007. 4 May 2007, Moscow: JSC Pharmstandard (“ ...
  32. [32]
    Russia Pharmstandard to float up to 40 pct in IPO | Reuters
    Aug 9, 2007 · Final pricing should be set by May 4. Pharmstandard has a small listing on Moscow's RTS exchange, but it called this a technical preparation for ...Missing: date | Show results with:date
  33. [33]
    Russian Pharmaceutical Market Projected to Reach $20 Billion by ...
    The Russian pharmaceutical market anticipates reaching $20 billion by 2025, fueled by an expanding middle class and a rising demand for advanced medical ...Missing: Boris | Show results with:Boris
  34. [34]
    Why Russia's Pharmaceutical Market Value Will Double in Four Years
    Mar 3, 2017 · By volume, generic drugs accounted for 85% of marketed drug sales. The Russian company Pharmstandard is one of the leading generic manufacturers ...
  35. [35]
    [PDF] Trends in pharma patent litigation in Russia - Gorodissky
    A battle between patent owners and generic companies has revealed different interpretations in the Russian judicial system. The law allows lawsuits to prevent ...Missing: Pharmstandard | Show results with:Pharmstandard
  36. [36]
    From Russia with drugs | Drug Discovery News
    Apparently in a growth mode, Pharmstandard acquired twocompanies in 2012, according to Igor Krylov, CEO, at a press conference on July25. In November 2012, the ...<|separator|>
  37. [37]
    Curaleaf Announces CEO Transition - Aug 7, 2024
    Aug 7, 2024 · Boris Jordan was the founding investor in Curaleaf in 2014, and then became Executive Chairman, a position he has held since 2015. He has made ...
  38. [38]
    Curaleaf Completes the Acquisition of Grassroots Creating the ...
    Jul 23, 2020 · With completion of the acquisition of Grassroots, Curaleaf is the world's largest cannabis company by revenue and the most diversified vertically integrated ...
  39. [39]
    Curaleaf Completes Acquisition of Select - Feb 3, 2020
    Feb 3, 2020 · Curaleaf's acquisition of Cura Partners, Inc. ("Cura"), owners of the Select brand, includes Select's manufacturing, distribution, marketing and ...
  40. [40]
    Curaleaf to Acquire Grassroots, Creating the World's Largest ...
    Jul 17, 2019 · Curaleaf will acquire Grassroots for total consideration of approximately $875 million, composed of $75 million in cash, 102.8 million subordinate voting ...
  41. [41]
    Curaleaf (CURLF) - Revenue - Companies Market Cap
    According to Curaleaf's latest financial reports the company's current revenue (TTM ) is $1.28 Billion USD. In 2024 the company made a revenue of $1.34 Billion ...
  42. [42]
    Curaleaf Holdings Revenue 2019-2025 | CURLF - Macrotrends
    Curaleaf Holdings revenue from 2019 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales ...
  43. [43]
    Curaleaf Reports Second Quarter 2025 Results
    Aug 6, 2025 · Net Revenue of $314.5 million, a year-over-year decrease of 8% compared to Q2 2024 revenue of $342.3 million. · Gross profit of $152.6 million ...Missing: 2020s | Show results with:2020s
  44. [44]
    Press Releases - Curaleaf Holdings, Inc. Investor Relations
    Feb 6, 2024. Curaleaf International Acquires Can4Med, Expanding Presence in Poland's Growing Medical Cannabis Market. Curaleaf International (the "Company ...
  45. [45]
    Curaleaf Takes Majority Stake And Forms Strategic Partnership With ...
    Curaleaf Takes Majority Stake And Forms Strategic Partnership With Germany's Four 20 Pharma In €20m Deal · Columbia Care To 'Wind Down' Operations In UK & Europe.Missing: expansion | Show results with:expansion
  46. [46]
    Is It Time To Go Global? Cannabis Continues To Grow Internationally
    Feb 18, 2025 · Earlier in 2024, Curaleaf expanded into the Czech Republic through a supply agreement with Astrasana Pharma and acquired Can4Med, a ...
  47. [47]
    [PDF] Curaleaf Investor Deck
    • In 2024, Europe has an estimated total addressable market of $246 billion(1) ... • Germany and the U.K. are key growth drivers and continue our investment in.
  48. [48]
    Curaleaf Holdings Announces Buyout of Minority Partner in Curaleaf ...
    Jul 8, 2025 · The acquisition strengthens the Company's control over its European operations, enabling enhanced strategic alignment across international ...
  49. [49]
    Curaleaf Buys Out Minority Partner in Curaleaf International
    Jul 8, 2025 · The transaction with an institutional investor brings the cannabis company's stake in its European holding company to 100%.Missing: Germany UK 2024
  50. [50]
    Top Companies in Cannabis Market - Canopy Growth Corporation ...
    Jul 24, 2025 · Curaleaf is a leading vertically integrated cannabis company in the US, operating across 23 states with 151 dispensaries and 19 cultivation and ...
  51. [51]
    Curaleaf Holdings Reports Increasing International Cannabis Sales ...
    Jul 20, 2025 · Curaleaf's international sales increased 74% year-over-year, with a 50% profit margin and positive cash flow, but the stock is undervalued due ...
  52. [52]
    Curaleaf Holdings Reports Q2 2025 Results and Expansion
    Aug 8, 2025 · Elevate Your Investing Strategy:​​ In its second quarter of 2025, Curaleaf reported a total revenue of $315 million, marking a 1.5% increase from ...Missing: hemp | Show results with:hemp
  53. [53]
    Top Multi-State Operator Cannabis Stocks in the U.S. — August ...
    Aug 14, 2025 · In its latest reported quarter, Curaleaf generated approximately $342 million in revenue, reflecting modest year-over-year growth. Gross margins ...Trulieve Cannabis Corp... · Curaleaf Holdings Inc... · Cresco Labs Inc. (crlbf)
  54. [54]
    Why Curaleaf Remains a Strong Sell Despite Recent Analyst ...
    Aug 17, 2025 · - Analysts upgrade Curaleaf, citing regulatory optimism and global expansion, but highlight unsustainable debt and operational risks. - ...
  55. [55]
    Russia's Abramovich Gave Largest US Weed Company Millions
    Dec 23, 2022 · “Curaleaf today doesn't have Roman Abramovich as a shareholder to the best of our knowledge.” Jordan said the financing went to Palliatech from ...
  56. [56]
    Leaked Files Show How a Putin Ally Bankrolled the US Weed Industry
    Feb 16, 2023 · He funded most of the $54 million for Jordan to start another cannabis venture fund called Measure 8 in 2017. He had shareholdings in Eaze, a ...
  57. [57]
    https://news.crbmonitor.com/2023/03/curaleafs-undisclosed-ties-to-sanctioned-oligarch-spur-regulatory-scrutiny/
  58. [58]
    Curaleaf's Undisclosed Ties to Sanctioned Oligarch Spur Regulatory ...
    Abramovich pumped over $400 million into the pockets of Curaleaf, its executive chairman Boris Jordan, and at least two of Curaleaf's top shareholders from ...
  59. [59]
    Cannabis MSO Curaleaf aims to end talk of US sanctions for ...
    Feb 28, 2022 · MarketWatch reported that Jordan owns 22% of Curaleaf's stock. Jordan has in the past praised Russian President Vladimir Putin. In a 2007 op ...Missing: influence | Show results with:influence
  60. [60]
    https://ir.curaleaf.com/2022-02-25-Curaleaf-Informs
  61. [61]
    Press Releases - Curaleaf Holdings, Inc. Investor Relations
    Feb 25, 2022 · Curaleaf, as an American company, is also not subject to and cannot be subject to, U.S. economic sanctions. Our Executive Chairman and largest ...Missing: risks | Show results with:risks<|separator|>
  62. [62]
    State Looking Into Loans Made To Curaleaf By Russian Billionaire's ...
    Jan 30, 2023 · The Massachusetts Cannabis Control Commission (CCC) had opened an investigation into whether Curaleaf's loans were properly reported to the state.Missing: achievements | Show results with:achievements
  63. [63]
    Russia Sanctions Pile Onto Political Risks for Marijuana Stocks
    Mar 7, 2022 · Sanctions against Russia following its invasion of Ukraine and a White House memo about marijuana stocks upended the industry last week.
  64. [64]
    Miami Beach penthouse will set you back $35million - Daily Mail
    Aug 9, 2017 · Boris is the founder of the private equity and advisory firm the Sputnik Group. Elizabeth, 46, is the CEO of Elizabeth Jordan Photography. The ...
  65. [65]
    Russian American businessman Jordan buys Miami Beach ...
    Jun 4, 2015 · His latest purchase is a 13,220-square-foot residence from David Arditi's 321 Ocean Drive LLC for $1,513 per square foot. The oceanfront unit ...
  66. [66]
    Russian Venture Capitalist Sells South Beach Penthouse ... - Forbes
    May 14, 2018 · Boris Jordan, the Russian banking pioneer and venture capitalist pouring money into the fledgling U.S. marijuana industry, sold his South ...Missing: York | Show results with:York
  67. [67]
    About - Jordan Russia Center
    The Jordan Center for the Advanced Study of Russia was established in 2011 thanks to a generous gift from the family of NYU alumni Boris and Elizabeth Jordan.Missing: education | Show results with:education
  68. [68]
    [PDF] Russia Engages the World - NYPL
    Major underwriting support for this exhibition has been provided by a generous gift from The Boris Jordan. Family. Additional support has been provided by ...
  69. [69]
    240701 Fireside Chat with Curaleaf Chairman, Boris Jordan ...
    Jul 9, 2024 · ... patient. Additionally, the Company supplies medical cannabis on a wholesale basis across Europe, including into Italy and Germany ...Missing: advocacy | Show results with:advocacy
  70. [70]
    Curaleaf Partners with The Baldwin Fund to Support Breast Cancer ...
    Sep 29, 2025 · Curaleaf Partners with The Baldwin Fund to Support Breast Cancer Research This October. Join Us in the Fight—Round Up for Research.
  71. [71]
    Curaleaf and The Baldwin Fund Partner to Raise Funds for Breast ...
    Oct 1, 2025 · This year's partnership will allow Curaleaf to scale its impact nationwide, uniting customers and communities around a shared goal of funding ...
  72. [72]
    Medical pot pioneer rips 'un-American' Hochul, NY regulators for ...
    May 11, 2025 · Boris Jordan, a pioneer of New York's legal marijuana sales to medical patients, has accused Gov. Kathy Hochul and state regulators of being ...Missing: achievements | Show results with:achievements
  73. [73]
    Curaleaf's Boris Jordan Talks 2025 Cannabis Trends
    Jan 9, 2025 · Boris Jordan joins us to talk about some of the key industry developments for 2025 and progress with the Trump administration.Missing: public persona advocate<|separator|>
  74. [74]
    Curaleaf's Boris Jordan Is America's Pot King - Bloomberg.com
    Dec 4, 2019 · In May he purchased Cura Partners, which makes the Select brand of vapes, then two months later bought Grassroots Cannabis, mainly for its ...Missing: Pharmstandard history<|separator|>